Q1 2025 Results Conference Call May 6, 2025 4:30 PM ETCompany ParticipantsBlake Beber - Head, IRSean Saint - President ...

Prospective controlled clinical trials are warranted to examine the current impact of GLP-1RA on non-diabetic PAD patients. Tirzepatide, a dual GLP-1/gastric inhibitory polypeptide (GIP ...

is often preceded by what was once termed "pre-diabetes". Now officially called "Non-Diabetic Hyperglycaemia (NDH)", this phase presents a vital chance for early action. Dr Najjar points out ...

A weekly dose of semaglutide, a drug used to manage diabetes and weight loss, was effective in 63% of patients at treating a ...

Continuous glucose monitoring can now spot early diabetes risks, offering a non-invasive alternative to traditional blood ...

Diabetes significantly impacts liver health, often leading to non-alcoholic fatty liver disease (NAFLD) due to insulin resistance and elevated blood sugar. Regular screening, including liver ...

non-diabetic individuals. "By design, CGMs sample interstitial fluid, which we assume is directly reflective of blood glucose, but yet could be influenced by other factors that impact glucose ...

Continuous glucose monitoring provides a new, less invasive method for evaluating diabetes risk. Fluctuations in blood ...

He covers federal public health agencies. There were 26.4 deaths per 100,000 people from diabetes, according to early death certificate data for the third quarter of 2024 published this month by ...

A breakthrough biosensor detects glucose in human tears at ultra-low concentrations, opening new avenues for wearable health ...

A recent study found that six cardiometabolic risk groups previously identified in middle-aged individuals can also be applied to older adults without diabetes. Using data from the KORA F4/FF4 study ...